{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:55:47Z","timestamp":1778853347326,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.phrs.2016.11.039","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T22:16:19Z","timestamp":1480716979000},"page":"267-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["PKC\u03b2II-mediated cross-talk of TRPV1\/CB2 modulates the glucocorticoid-induced osteoclast overactivity"],"prefix":"10.1016","volume":"115","author":[{"given":"Giulia","family":"Bellini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Torella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livio","family":"Luongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Punzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Colacurci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabatino","family":"Maione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2016.11.039_bib0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/phrs.2002.0969","article-title":"Molecular mechanisms of immunomodulatory activity of glucocorticoids","volume":"45","author":"Riccardi","year":"2002","journal-title":"Pharmacol. Res."},{"issue":"Suppl. 8","key":"10.1016\/j.phrs.2016.11.039_bib0010","first-page":"218","article-title":"[Adverse effects of glucocorticoids","volume":"65","author":"Sato","year":"2007","journal-title":"Nihon Rinsho"},{"issue":"1","key":"10.1016\/j.phrs.2016.11.039_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rdc.2015.08.005","article-title":"Glucocorticoid-induced osteoporosis","volume":"42","author":"Whittier","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"1","key":"10.1016\/j.phrs.2016.11.039_bib0020","doi-asserted-by":"crossref","first-page":"e000014","DOI":"10.1136\/rmdopen-2014-000014","article-title":"Glucocorticoid-induced osteoporosis","volume":"1","author":"Briot","year":"2015","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.phrs.2016.11.039_bib0025","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.bone.2011.02.005","article-title":"Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis","volume":"48","author":"Kalpakcioglu","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.phrs.2016.11.039_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00198-005-1923-3","article-title":"High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass","volume":"17","author":"Natsui","year":"2006","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.phrs.2016.11.039_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"van Staa","year":"2006","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"10.1016\/j.phrs.2016.11.039_bib0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00198-004-1606-5","article-title":"Are inhaled corticosteroids associated with an increased risk of fracture in children?","volume":"15","author":"van Staa","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"10","key":"10.1016\/j.phrs.2016.11.039_bib0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.phrs.2016.11.039_bib0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.phrs.2016.11.039_bib0055","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.phrs.2016.11.039_bib0060","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.phrs.2016.11.039_bib0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","article-title":"Oral glucocorticoid use is associated with an increased risk of fracture","volume":"15","author":"Steinbuch","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.phrs.2016.11.039_bib0070","first-page":"1337","article-title":"[Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis]","volume":"23","author":"Hayakawa","year":"2013","journal-title":"Clin. Calcium"},{"issue":"7","key":"10.1016\/j.phrs.2016.11.039_bib0075","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm1255","article-title":"Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors","volume":"11","author":"Idris","year":"2005","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2016.11.039_bib0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2826.2008.01675.x","article-title":"Endocannabinoids and the regulation of bone metabolism","volume":"20","author":"Bab","year":"2008","journal-title":"J. Neuroendocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2016.11.039_bib0085","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bone.2008.10.056","article-title":"The endovanilloid\/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption","volume":"44","author":"Rossi","year":"2009","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.phrs.2016.11.039_bib0090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bone.2011.01.001","article-title":"The endovanilloid\/endocannabinoid system: a new potential target for osteoporosis therapy","volume":"48","author":"Rossi","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.phrs.2016.11.039_bib0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.phrs.2007.09.004","article-title":"Endocannabinoid regulation of relapse mechanisms","volume":"56","author":"Fattore","year":"2007","journal-title":"Pharmacol. Res."},{"issue":"1607","key":"10.1016\/j.phrs.2016.11.039_bib0100","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1098\/rstb.2011.0382","article-title":"Why do cannabinoid receptors have more than one endogenous ligand?","volume":"367","author":"Di Marzo","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2016.11.039_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","article-title":"The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation","volume":"60","author":"Di Marzo","year":"2009","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.phrs.2016.11.039_bib0110","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1111\/bph.12542","article-title":"The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice","volume":"171","author":"Rossi","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.11.039_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2014.01.002","article-title":"Corticosteroids modulate the expression of the PKC-anchoring protein RACK-1 and cytokine release in THP-1 cells","volume":"81","author":"Corsini","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2016.11.039_bib0120","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s11064-008-9698-5","article-title":"The PKC and ERK\/MAPK pathways regulate glucocorticoid action on TRH transcription","volume":"33","author":"Cote-Velez","year":"2008","journal-title":"Neurochem. Res."},{"issue":"10","key":"10.1016\/j.phrs.2016.11.039_bib0125","doi-asserted-by":"crossref","first-page":"747","DOI":"10.14348\/molcells.2014.0220","article-title":"PKCbeta positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3beta","volume":"37","author":"Shin","year":"2014","journal-title":"Mol. Cells"},{"issue":"6","key":"10.1016\/j.phrs.2016.11.039_bib0130","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/jcp.24858","article-title":"Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-kappaB and NFAT activity","volume":"230","author":"Yao","year":"2015","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2016.11.039_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1476-9255-10-12","article-title":"Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps","volume":"10","author":"Gray","year":"2013","journal-title":"J. Inflamm. (Lond)"},{"issue":"8","key":"10.1016\/j.phrs.2016.11.039_bib0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5483\/BMBRep.2010.43.8.524","article-title":"New understanding of glucocorticoid action in bone cells","volume":"43","author":"Kim","year":"2010","journal-title":"BMB Rep."},{"issue":"4","key":"10.1016\/j.phrs.2016.11.039_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tem.2013.12.006","article-title":"Glucocorticoids and bone: local effects and systemic implications","volume":"25","author":"Henneicke","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2016.11.039_bib0150","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2016.11.039_bib0155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1196\/annals.1402.057","article-title":"Glucocorticoids and the osteoclast","volume":"1116","author":"Kim","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2016.11.039_bib0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","article-title":"Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor","volume":"11","author":"Rauch","year":"2010","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.phrs.2016.11.039_bib0165","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","article-title":"Glucocorticoids suppress bone formation via the osteoclast","volume":"116","author":"Kim","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2016.11.039_bib0170","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","article-title":"Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength","volume":"145","author":"O'Brien","year":"2004","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2016.11.039_bib0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00774-007-0821-5","article-title":"Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study","volume":"26","author":"Kuroki","year":"2008","journal-title":"J. Bone Miner. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2016.11.039_bib0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2016.11.039_bib0185","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1172\/JCI68062","article-title":"Steroids and osteoporosis: the quest for mechanisms","volume":"123","author":"Manolagas","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.039_bib0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.phrs.2015.06.010","article-title":"CB(2) and TRPV(1) receptors oppositely modulate in vitro human osteoblast activity","volume":"99","author":"Rossi","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2016.11.039_bib0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phrs.2012.10.017","article-title":"The 17-beta-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression","volume":"68","author":"Rossi","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.phrs.2016.11.039_bib0200","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3324\/haematol.2014.104463","article-title":"Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels","volume":"99","author":"Rossi","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.phrs.2016.11.039_bib0205","doi-asserted-by":"crossref","first-page":"8246","DOI":"10.1523\/JNEUROSCI.0278-14.2014","article-title":"The basal thermal sensitivity of the TRPV1 ion channel is determined by PKCbetaII","volume":"34","author":"Li","year":"2014","journal-title":"J. Neurosci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816310994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816310994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T07:00:14Z","timestamp":1536217214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816310994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":41,"alternative-id":["S1043661816310994"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.11.039","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PKC\u03b2II-mediated cross-talk of TRPV1\/CB2 modulates the glucocorticoid-induced osteoclast overactivity","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}